11 active not recruiting. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Active not recruiting 11 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 4 | Active not recruiting | Johnson & Johnson Private Limited | 75 | 2025-05-22 | 2026-09-25 |
| A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis Efanesoctocog alfa - Haemophilia A (Moderate or Severe), Hemophilia, Classic | Phase 4 | Active not recruiting | Swedish Orphan Biovitrum | 37 | 2024-12-19 | 2026-04-30 |
| Hepatoprotective Measures for Children at High Risk of NAFLD Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise - Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight | Phase 4 | Active not recruiting | Ain Shams University | 200 | 2023-11-19 | 2025-04-09 |
| Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Active not recruiting | Zhengzhou University | 34 | 2023-10-21 | 2025-07-01 |
| Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy PCV20 - Lymphoma | Phase 4 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2023-10-06 | 2026-09-15 |
| Crizotinib Continuation Clinical Study crizotinib - NSCLC, ALCL | Phase 4 | Active not recruiting | Pfizer | 27 | 2021-12-27 | 2026-03-30 |
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Velcade, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Active not recruiting | University of Turin, Italy | 450 | 2019-01-03 | 2025-12-03 |
| CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Combined chemotherapy with or without involved-field radiotherapy - Hodgkin Lymphoma | Phase 4 | Active not recruiting | Children's Cancer Group, China | 200 | 2018-04-01 | 2026-03-19 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Active not recruiting | Pharmacyclics Switzerland GmbH | 297 | 2017-05-22 | 2025-10-30 |
| Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) 2-dose PCV13, 1-dose PCV13 - Multiple Myeloma | Phase 4 | Active not recruiting | National Taiwan University Hospital | 101 | 2016-03-23 | 2025-09-04 |
Multiple Myeloma (3) · Carcinoma, Non-Small-Cell Lung (1) · Graft vs Host Disease (1) · Granuloma, Plasma Cell (1) · Hemophilia A (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphatic Diseases (8) · Hematologic Diseases (7) · Hemorrhagic Disorders (5) · Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Hemostatic Disorders (4) · Lymphoma (4) · Neoplasms, Plasma Cell (4) · Paraproteinemias (4)
Azacitidine (1) · Bortezomib (1) · Crizotinib (1) · Dasatinib (1) · Dexamethasone (1) · Docosahexaenoic Acids (1) · Exercise (1) · Lenalidomide (1) · Melphalan (1) · Prednisone (1) · Ursodeoxycholic Acid (1) · daratumumab (1) · ibrutinib (1) · zanubrutinib (1)
Ain Shams University (1) · BeiGene (1) · Children's Cancer Group, China (1) · Johnson & Johnson Private Limited (1) · M.D. Anderson Cancer Center (1) · National Taiwan University Hospital (1) · Pfizer (1) · Pharmacyclics Switzerland GmbH (1) · Swedish Orphan Biovitrum (1) · University of Turin, Italy (1) · Zhengzhou University (1)
China (4) · Italy (4) · Taiwan (3) · Russia (2) · Spain (2) · Sweden (2) · United States (2) · Australia (1) · Canada (1) · Czechia (1) · Egypt (1) · France (1) · Hungary (1) · India (1) · Japan (1)
Fareed Khawaja, MD (1) · Fatma SE Ebeid, Professor of pediatrics (1) · Hsin-Yun Sun, M.D., Ph.D. (1) · Kevin Wu (1) · Manal H El-Sayed, Professor of pediatrics (1)
PMID 23275102, PMID 25311218, PMID 31539308
2016 (1)